NAUT: Proteoform roadmap advances toward Voyager launch in 2027 and 20 assays by mid-2028

What happened

The article states Q3 revenue was $200,000 and net loss was $15.6M, with cash runway projected into Q1 2028. The roadmap targets Voyager pre-orders in early 2027, shipments in mid-2027, and 20 assays by mid-2028.

Confirmed

Global impact / market context

Voyager shipments in mid-2027 and 20 assays by mid-2028 are the company's path toward product revenue beyond the current $200,000 a quarter. Reaching these targets matters because the projected cash runway into Q1 2028 leaves little room before launch.

Analyst inference

The company is spending heavily relative to its revenue, reporting a $15.6M net loss against $200,000 in sales. That gap means results depend on the Voyager launch timing and assay rollout, and any delay could pressure the cash position before Q1 2028.

Analyst inference

What to watch

1. Voyager pre-orders are targeted for early 2027 and shipments for mid-2027. Watch whether the company reports progress on these dates, given the projected cash runway into Q1 2028. Confirmed
2. The roadmap proposes reaching 20 assays by mid-2028. Each added assay could broaden what customers can test, so track announcements of assay availability as evidence the proposal is being delivered. Proposed
3. Watch whether revenue grows from $200,000 and whether the $15.6M net loss narrows as launch nears. A widening loss without sales growth would shorten the runway before Q1 2028. Analyst inference

Evidence

• Original source link unavailable